StockTipsArenaBeta

BUY Alembic Pharmaceuticals Limited — BOB Capital Markets

BUYAlembic Pharmaceuticals Limited
Alembic Pharmaceuticals share price target & all analyst calls

byBOB Capital MarketsHorizon: NA (inferred 1 year)6 Aug 2025via Institutional / Brokerage Research

Entry₹948.25Inferred
Target₹1,101
Total upside +16.11% (call closed)
Stop lossNot given
At expiry₹818.26 Aug 2026, 3:30 pm
Expired-13.71%
Follow BOB Capital Markets for new calls(63% target hit, 357 closed calls)Get alertsWatch APLLTD for new buy/sell callsGet alertsSee 3 active Long-term calls on APLLTDSee 212 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 6 Aug 2026
17 supporting5 neutral0 opposing
Supports the BUY call (17)

Alembic Pharmaceuticals reported a 26% YoY increase in revenue to Rs. 2150 Cr and a 12% YoY increase in Profit After Tax to Rs. 173 Cr for Q1 FY27. EBITDA also saw a 21% YoY rise. The company highligh

BSE · Company Update·4 Aug · 2d ago

(opens in new tab)

Alembic Pharmaceuticals reported Q1 FY27 financial results with revenue up 26% to Rs. 2150 Cr and EBITDA up 21% YoY. The company highlighted strong growth across businesses, driven by volume growth an

BSE · Company Update·4 Aug · 2d ago

(opens in new tab)

Alembic Pharma gains on USFDA nod for generic constipation drug targeting $100 million US market

NewsCnbc-Tv18·28 Jul · 1w ago

(opens in new tab)

Alembic Pharmaceuticals Ltd has received final approval from the USFDA for its Prucalopride Tablets in 1 mg and 2 mg strengths.

BSE · Company Update·28 Jul · 1w ago

(opens in new tab)

Alembic Pharmaceuticals Ltd's partner, NATCO Pharma Limited, has received tentative approval from the USFDA for Olaparib Tablets 100 mg and 150 mg.

BSE · Company Update·18 Jul · 3w ago

(opens in new tab)
Neutral / worth noting (5)

Alembic Pharmaceuticals Limited announced the approval of its consolidated and standalone unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Report from sta

NSE · Outcome of Board Meeting·4 Aug · 2d ago

(opens in new tab)

Alembic Pharmaceuticals Ltd announced the approval of its consolidated and standalone unaudited financial results for the quarter ended June 30, 2026, along with the Limited Review Report from statuto

BSE · Board Meeting·4 Aug · 2d ago

(opens in new tab)

Alembic Pharmaceuticals Limited's Board of Directors has approved the Consolidated and Standalone Unaudited Financial Results for the quarter ended June 30, 2026, along with the Limited Review Report

NSE · Outcome of Board Meeting·4 Aug · 2d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Alembic Pharmaceuticals

All analyst calls on Alembic Pharmaceuticals

More from BOB Capital Markets

Every call and its outcome